Judith Anne W Chapman

Summary

Affiliation: Queen's University
Country: Canada

Publications

  1. pmc Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial
    Vivien H C Bramwell
    Breast Cancer Res 16:R8. 2014
  2. pmc Innovative estimation of survival using log-normal survival modelling on ACCENT database
    J W Chapman
    NCIC Clinical Trials Group, Queen s University, 10 Stuart Street, Kingston, Ontario, Canada
    Br J Cancer 108:784-90. 2013
  3. ncbi Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis
    Judith Anne W Chapman
    Department of Public Health Sciences, Faculty of Medicine, University of Toronto, and Department of Laboratory Medicine and Pathology, St Michael s Hospital, Toronto, Ontario, Canada
    Breast J 12:37-47. 2006
  4. pmc Ductal carcinoma in situ of the breast (DCIS) with heterogeneity of nuclear grade: prognostic effects of quantitative nuclear assessment
    Judith Anne W Chapman
    National Cancer Institute of Canada Clinical Trials Group, Queen s University, 10 Stuart Street, Kingston, Ontario K7L 3N6, Canada
    BMC Cancer 7:174. 2007
  5. pmc Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer
    Judith Anne W Chapman
    National Cancer Institute of Canada Clinical Trials Group, Queen s University, 10 Stuart St, Kingston, ON, Canada
    J Natl Cancer Inst 100:252-60. 2008
  6. pmc Heterogeneity Between Ducts of the Same Nuclear Grade Involved by Duct Carcinoma In Situ (DCIS) of the Breast
    Naomi A Miller
    Department of Pathology, University Health Network, 200 Elizabeth St, Eaton 11 444, Toronto, Ontario, Canada M5G 2C4
    Cancer Inform 9:209-16. 2010
  7. doi Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14
    Kathleen I Pritchard
    Sunnybrook Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 29:3869-76. 2011
  8. pmc Disease-specific survival for limited-stage small-cell lung cancer affected by statistical method of assessment
    Patricia Tai
    University of Saskatchewan, Faculty of Medicine, Saskatoon, Saskatchewan, Canada
    BMC Cancer 7:31. 2007
  9. pmc Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial
    Vered Stearns
    Vered Stearns, Kimmel Cancer Center, Johns Hopkins, Baltimore, MD Judith Anne W Chapman, Aurélie Le Maitre, Jessica Kundapur, and Lois E Shepherd, NCIC Clinical Trials Group, Queen s University, Kingston Kathleen I Pritchard, Sunnybrook Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada Cynthia X Ma, Siteman Cancer Center, Washington University, St Louis, MO Matthew J Ellis, Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX James N Ingle, Mayo Clinic, Rochester, MN G Thomas Budd, Cleveland Clinic, Cleveland, OH George W Sledge, Stanford University, San Francisco, CA Pedro E R Liedke and Paul E Goss, Harvard University Paul E Goss, Avon International Breast Cancer Research Program, Massachusetts General Hospital, Boston, MA Manuela Rabaglio, Inselspital University Hospital and International Breast Cancer Study Group Coordinating Center, Berne, Switzerland and Pedro E R Liedke, Hospital de Clínicas de Porto Alegre and Instituto do Cancer Mãe de Deus, France
    J Clin Oncol 33:265-71. 2015
  10. doi Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials
    Edward L Korn
    Biometric Research Branch, EPN 8129, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 26:527-34. 2008

Collaborators

Detail Information

Publications12

  1. pmc Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial
    Vivien H C Bramwell
    Breast Cancer Res 16:R8. 2014
    ..In metastatic breast cancer, we previously demonstrated that elevated OPN in primary tumor and blood was associated with poor prognosis...
  2. pmc Innovative estimation of survival using log-normal survival modelling on ACCENT database
    J W Chapman
    NCIC Clinical Trials Group, Queen s University, 10 Stuart Street, Kingston, Ontario, Canada
    Br J Cancer 108:784-90. 2013
    ..We hypothesised substantive differences in survival estimation with log-normal modelling rather than standard Kaplan-Meier or Cox approaches...
  3. ncbi Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis
    Judith Anne W Chapman
    Department of Public Health Sciences, Faculty of Medicine, University of Toronto, and Department of Laboratory Medicine and Pathology, St Michael s Hospital, Toronto, Ontario, Canada
    Breast J 12:37-47. 2006
    ..Estimated prognoses may differ substantially by survival analysis model type, by amounts that might affect patient management, and we think that the log-normal model has a major advantage over the Cox model for survival analysis...
  4. pmc Ductal carcinoma in situ of the breast (DCIS) with heterogeneity of nuclear grade: prognostic effects of quantitative nuclear assessment
    Judith Anne W Chapman
    National Cancer Institute of Canada Clinical Trials Group, Queen s University, 10 Stuart Street, Kingston, Ontario K7L 3N6, Canada
    BMC Cancer 7:174. 2007
    ..Here, we used image analysis in addition to histologic evaluation to determine if quantification of nuclear features could provide additional prognostic information and hence impact prognostic assessments...
  5. pmc Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer
    Judith Anne W Chapman
    National Cancer Institute of Canada Clinical Trials Group, Queen s University, 10 Stuart St, Kingston, ON, Canada
    J Natl Cancer Inst 100:252-60. 2008
    ..We examined factors associated with cause-specific death in a large cohort of breast cancer patients treated with extended adjuvant endocrine therapy...
  6. pmc Heterogeneity Between Ducts of the Same Nuclear Grade Involved by Duct Carcinoma In Situ (DCIS) of the Breast
    Naomi A Miller
    Department of Pathology, University Health Network, 200 Elizabeth St, Eaton 11 444, Toronto, Ontario, Canada M5G 2C4
    Cancer Inform 9:209-16. 2010
    ..05). Also, we compared image features for nuclei in patients with single grade to those with the same grade in patients with multiple grades using t-tests...
  7. doi Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14
    Kathleen I Pritchard
    Sunnybrook Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 29:3869-76. 2011
    ..This trial was undertaken to assess whether octreotide would lower insulin and IGF-1 levels and reduce risk of breast cancer recurrence...
  8. pmc Disease-specific survival for limited-stage small-cell lung cancer affected by statistical method of assessment
    Patricia Tai
    University of Saskatchewan, Faculty of Medicine, Saskatoon, Saskatchewan, Canada
    BMC Cancer 7:31. 2007
    ..There might be substantive differences from the results using these models for the same patients, if different statistical methods were used, for example, Boag log-normal (cure-rate model), or log-normal survival analysis...
  9. pmc Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial
    Vered Stearns
    Vered Stearns, Kimmel Cancer Center, Johns Hopkins, Baltimore, MD Judith Anne W Chapman, Aurélie Le Maitre, Jessica Kundapur, and Lois E Shepherd, NCIC Clinical Trials Group, Queen s University, Kingston Kathleen I Pritchard, Sunnybrook Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada Cynthia X Ma, Siteman Cancer Center, Washington University, St Louis, MO Matthew J Ellis, Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX James N Ingle, Mayo Clinic, Rochester, MN G Thomas Budd, Cleveland Clinic, Cleveland, OH George W Sledge, Stanford University, San Francisco, CA Pedro E R Liedke and Paul E Goss, Harvard University Paul E Goss, Avon International Breast Cancer Research Program, Massachusetts General Hospital, Boston, MA Manuela Rabaglio, Inselspital University Hospital and International Breast Cancer Study Group Coordinating Center, Berne, Switzerland and Pedro E R Liedke, Hospital de Clínicas de Porto Alegre and Instituto do Cancer Mãe de Deus, France
    J Clin Oncol 33:265-71. 2015
    ..We hypothesized that MA.27 anastrozole- or exemestane-treated patients with new or worsening vasomotor and/or joint symptoms would have improved RFS...
  10. doi Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials
    Edward L Korn
    Biometric Research Branch, EPN 8129, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 26:527-34. 2008
    ....
  11. ncbi Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system
    Clifford A Hudis
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:2127-32. 2007
    ....